Christopher W. Peterson

Christopher W. Peterson

Auto-generated profile, based on publicly available information

Christopher W. Peterson

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
AZAnjie Zhen
Anjie Zhen
CPChristopher W. Peterson
Christopher W. Peterson
MCMayra A. Carrillo
Mayra A. Carrillo
SRSowmya Somashekar Reddy
Sowmya Somashekar Reddy
CYCindy S. Youn
Cindy S. Youn
SKScott G. Kitchen
Scott G. Kitchen
Chimeric Antigen Receptor (CAR) T-cells have emerged as a powerful immunotherapy for various forms of cancer and show promise in treating HIV-1 infection. However, significant limitations are persistence and whether peripheral T cell-based products can respond to malignant or infected cells that may reappear months or years after treatment remains unclear. Hematopoietic Stem/Progenitor Cells (HSPCs) are capable of long-term engraftment and have the potential to overcome these limitations. Here, we report the use of a protective CD4 chimeric antigen receptor (C46CD4CAR) to redirect HSPC-derived T-cells against simian/human immunodeficiency virus (SHIV) infection in pigtail macaques. CAR-containing cells persisted for more than 2 years without any measurable toxicity and were capable of multilineage engraftment. Combination antiretroviral therapy (cART) treatment followed by cART withdrawal resulted in lower viral rebound in CAR animals relative to controls, and demonstrated an immune memory-like response. We found CAR-expressing cells in multiple lymphoid tissues, decreased tissue-associated SHIV RNA levels, and substantially higher CD4/CD8 ratios in the gut as compared to controls. These results show that HSPC-derived CAR T-cells are capable of long-term engraftment and immune surveillance. This study demonstrates for the first time the safety and feasibility of HSPC-based CAR therapy in a large animal preclinical model. Hematopoietic Stem/Progenitor Cell (HSPC) based gene therapy can be used to treat many infectious and genetic diseases. Here, we used an HSPC-based approach to redirect and enhance host immunity against HIV-1. We engineered HSPCs to carry chimeric antigen receptor (CAR) genes that detect and destroy HIV-infected cells. CAR therapy has shown huge potential in the treatment of cancer, but has only been applied in peripheral blood T-cells. HSPC-based CAR therapy has several benefits over T cell gene therapy, as it allows for normal T cell development, selection, and persistence of the engineered cells for the lifetime of the patient. We used a CAR molecule that hijacks the essential interaction between the virus and the cell surface molecule CD4 to redirect HSPC-derived T-cells against infected cells. We observed >2 years of stable production of CAR-expressing cells without any adverse events, and wide distribution of these cells in lymphoid tissues and gastrointestinal tract, which are major anatomic sites for HIV replication and persistence in suppressed patients. Most importantly, HSPC-derived CAR T-cells functionally responded to infected cells. This study demonstrates for the first time the safety and feasibility of HSPC based therapy utilizing an HIV-specific CAR for suppressed HIV infection.

31 July 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
OHOlivier Humbert
Olivier Humbert
SRStefan Radtke
Stefan Radtke
CSClare Samuelson
Clare Samuelson
RCRay R. Carrillo
Ray R. Carrillo
APAnai M. Perez
Anai M. Perez
HKHans-Peter Kiem
Hans-Peter Kiem
Reactivation of fetal hemoglobin (HbF) is being pursued as a treatment strategy for hemoglobinopathies. Here, we evaluated the therapeutic potential of hematopoietic stem and progenitor cells (HSPCs) edited with the CRISPR-Cas9 nuclease platform to recapitulate naturally occurring mutations identified in individuals who express increased amounts of HbF, a condition known as hereditary persistence of HbF. CRISPR-Cas9 treatment and transplantation of HSPCs purified on the basis of surface expression of the CD34 receptor in a nonhuman primate (NHP) autologous transplantation model resulted in up to 30% engraftment of gene-edited cells for >1 year. Edited cells effectively and stably reactivated HbF, as evidenced by up to 18% HbF-expressing erythrocytes in peripheral blood. Similar results were obtained by editing highly enriched stem cells, defined by the markers CD34+CD90+CD45RA−, allowing for a 10-fold reduction in the number of transplanted target cells, thus considerably reducing the need for editing reagents. The frequency of engrafted, gene-edited cells persisting in vivo using this approach may be sufficient to ameliorate the phenotype for a number of genetic diseases.

8 October 2020 in Blood
Verified
Journal Article
Open access
PDF file
BRBlake J. Rust
Blake J. Rust
LKLeslie S. Kean
Leslie S. Kean
LCLucrezia Colonna
Lucrezia Colonna
KBKatherine E. Brandenstein
Katherine E. Brandenstein
NPNikhita H. Poole
Nikhita H. Poole
CPChristopher W. Peterson
Christopher W. Peterson
This article has been retracted at the request of the Authors. Please see Elsevier's Article Correction, Retraction and Removal Policy (https://www.elsevier.com/locate/withdrawalpolicy). The study's authors conducted a re-evaluation of their work, after being unable to repeat the findings with a new data set. They report that upon this re-evaluation, the published flow cytometry conflicts with new CAR PCR data, thus nullifying the original hypothesis. The Editors acknowledge and appreciate the transparency of the authors for bringing this issue to the journal's attention. Authors Rust, Kean, Colonna, Obenza, Ellis, Fennessey, Keele, Jerome, Riley, Kiem, and Peterson approve of the retraction. Authors Brandenstein, Poole, Enstrom, Maldini, and Huang did not respond. A follow-up study related to this retracted paper has now been published in Blood (https://dx.doi.org/10.1182/blood.2025032142).

1 November 2021 in Molecular Therapy
Verified
Journal Article
Open access
LMLucy H. Maynard
Lucy H. Maynard
OHOlivier Humbert
Olivier Humbert
CPChristopher W. Peterson
Christopher W. Peterson
HKHans-Peter Kiem
Hans-Peter Kiem
Although genome editing technologies have the potential to revolutionize the way we treat human diseases, barriers to successful clinical implementation remain. Increasingly, preclinical large animal models are being used to overcome these barriers. In particular, the immunogenicity and long-term safety of novel gene editing therapeutics must be evaluated rigorously. However, short-lived small animal models, such as mice and rats, cannot address secondary pathologies that may arise years after a gene editing treatment. Likewise, immunodeficient mouse models by definition lack the ability to quantify the host immune response to a novel transgene or gene-edited locus. Large animal models, including dogs, pigs, and non-human primates (NHPs), bear greater resemblance to human anatomy, immunology, and lifespan and can be studied over longer timescales with clinical dosing regimens that are more relevant to humans. These models allow for larger scale and repeated blood and tissue sampling, enabling greater depth of study and focus on rare cellular subsets. Here, we review current progress in the development and evaluation of novel genome editing therapies in large animal models, focusing on applications in human immunodeficiency virus 1 (HIV-1) infection, cancer, and genetic diseases including hemoglobinopathies, Duchenne muscular dystrophy (DMD), hypercholesterolemia, and inherited retinal diseases.

11 January 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
IBIsaac M. Barber-Axthelm
Isaac M. Barber-Axthelm
VBValerie Barber-Axthelm
Valerie Barber-Axthelm
KSKai Yin Sze
Kai Yin Sze
AZAnjie Zhen
Anjie Zhen
GSGajendra W. Suryawanshi
Gajendra W. Suryawanshi
CPChristopher W. Peterson
Christopher W. Peterson
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with CCR5 – donor cells is the only treatment known to cure HIV-1 in patients with underlying malignancy. This is likely due to a donor cell–mediated graft-versus-host effect targeting HIV reservoirs. Allo-HSCT would not be an acceptable therapy for most people living with HIV due to the transplant-related side effects. Chimeric antigen receptor (CAR) immunotherapies specifically traffic to malignant lymphoid tissues (lymphomas) and, in some settings, are able to replace allo-HSCT. Here, we quantified the engraftment of HSC-derived, virus-directed CAR T cells within HIV reservoirs in a macaque model of HIV infection, using potentially novel IHC assays. HSC-derived CAR cells trafficked to and displayed multilineage engraftment within tissue-associated viral reservoirs, persisting for nearly 2 years in lymphoid germinal centers, the brain, and the gastrointestinal tract. Our findings demonstrate that HSC-derived CAR + cells reside long-term and proliferate in numerous tissues relevant for HIV infection and cancer.

1 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KEKarsten Eichholz
Karsten Eichholz
YFYoshinori Fukazawa
Yoshinori Fukazawa
CPChristopher W. Peterson
Christopher W. Peterson
FHFrancoise Haeseleer
Francoise Haeseleer
MMManuel Medina
Manuel Medina
LCLawrence Corey
Lawrence Corey
Programmed cell death protein 1 (PD-1) is an immune checkpoint marker commonly expressed on memory T cells and enriched in latently HIV-infected CD4 + T cells. We engineered an anti–PD-1 chimeric antigen receptor (CAR) to assess the impact of PD-1 depletion on viral reservoirs and rebound dynamics in SIVmac239–infected rhesus macaques (RMs). Adoptive transfer of anti–PD-1 CAR T cells was done in 2 SIV-naive and 4 SIV-infected RMs on antiretroviral therapy (ART). In 3 of 6 RMs, anti–PD-1 CAR T cells expanded and persisted for up to 100 days concomitant with the depletion of PD-1 + memory T cells in blood and tissues, including lymph node CD4 + follicular helper T (TFH) cells. Loss of TFH cells was associated with depletion of detectable SIV RNA from the germinal center (GC). However, following CAR T infusion and ART interruption, there was a marked increase in SIV replication in extrafollicular portions of lymph nodes, a 2-log higher plasma viremia relative to controls, and accelerated disease progression associated with the depletion of CD8 + memory T cells. These data indicate anti–PD-1 CAR T cells depleted PD-1 + T cells, including GC TFH cells, and eradicated SIV from this immunological sanctuary.